Suppr超能文献

类风湿关节炎治疗用利妥昔单抗后心肌梗死:二者是否有关联?

Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?

机构信息

Department of Rheumatology, Jan van Breemen Research Institute, Reade P.O. Box 58271, 1040 HG, Amsterdam, The Netherlands.

出版信息

Curr Pharm Des. 2014;20(4):496-9. doi: 10.2174/13816128113199990386.

Abstract

Rituximab is an anti-CD20 monoclonal antibody often used in the treatment of rheumatoid arthritis (RA). Infusion reactions sometimes develop following rituximab administration. Delayed complications are rare. Acute coronary syndromes are listed as sideeffects of rituximab therapy. We report two cases of acute myocardial infarction following rituximab therapy for RA and review the literature regarding cardiac events in patients treated with rituximab. We would like to raise awareness of this possible complication in patients treated with rituximab.

摘要

利妥昔单抗是一种抗 CD20 单克隆抗体,常用于治疗类风湿关节炎(RA)。利妥昔单抗给药后有时会发生输注反应。迟发性并发症罕见。急性冠状动脉综合征被列为利妥昔单抗治疗的副作用。我们报告了两例 RA 患者接受利妥昔单抗治疗后发生急性心肌梗死的病例,并回顾了利妥昔单抗治疗患者心脏事件的文献。我们希望提高接受利妥昔单抗治疗的患者对此种可能并发症的认识。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验